Kivala (Abacavir, Lamivudine)

Abacavir is a nucleoside analogue that, after intracellular phosphorylation, mimics natural nucleotides and is incorporated into viral DNA by HIV reverse transcriptase. This incorporation terminates the DNA chain, preventing further viral replication and helping to control HIV infection.

The specific dose of Kivala is determined by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and the overall antiretroviral regimen. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety of Kivala in pregnancy or while breastfeeding has not been fully established. It should be used only if the potential benefits to the mother outweigh any possible risks to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Kivala, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Kivala combines two nucleoside reverse transcriptase inhibitors, offering a dual‑NRTI backbone that is comparable to other fixed‑dose combinations such as tenofovir/emtricitabine. Choice of regimen depends on resistance profiles, tolerability, comorbidities and clinician preference.

Kivala should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Kivala is taken orally, usually with or without food, as directed by the prescribing physician. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include hypersensitivity reactions that may involve fever, rash, and organ involvement, as well as severe liver injury, lactic acidosis, neutropenia, and rare skin conditions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if any of these symptoms occur.

Kivala should be avoided in patients with known hypersensitivity to abacavir, lamivudine, or any component of the formulation. It is also contraindicated in individuals with severe hepatic impairment or those who cannot be monitored for potential serious adverse reactions.